ライフサイエンスコーパス: contrast-enhanced CT

1 ecember 2004, patients underwent intravenous contrast-enhanced CT.

2 4, patients underwent intravenous and rectal contrast-enhanced CT.

3 st-enhanced CT and 193 underwent intravenous contrast-enhanced CT.

4 0 patients who underwent portal venous phase contrast-enhanced CT.

5 at routine chest radiography should undergo contrast-enhanced CT.

6 patients with proved HCC underwent biphasic contrast-enhanced CT.

7 life (except for a patient) and pre-surgery contrast-enhanced CT.

8 er types, primarily due to late diagnosis on contrast-enhanced CT.

9 urvival (PFS) was investigator-assessed with contrast-enhanced CT.

10 -proven gastric cancer underwent multiphasic contrast-enhanced CT.

11 ssary extended lymphadenectomy compared with contrast-enhanced CT.

12 a inhibitor (FAPI)-46 PET,(18)F-FDG PET, and contrast-enhanced CT.

13 s [MPP]), and blood flow measured by dynamic contrast-enhanced CT.

14 edicated CT and abdominopelvic sonography or contrast-enhanced CT.

15 /CT, and in all 7, thrombi were confirmed on contrast-enhanced CT.

16 best coregistered to the fallopian tubes on contrast-enhanced CT.

17 rombus only with additional information from contrast-enhanced CT.

18 02 non-contrast-enhanced CTs and a set of 96 contrast-enhanced CTs.

19 andard error of the mean]), followed by dual-contrast-enhanced CT (112.4 HU +/- 1.2), iohexol-enhance

20 e the accuracy of combined (18)F-FDG PET and contrast-enhanced CT ((18)F-FDG PET/CT), multidetector C

21 All patients underwent contrast-enhanced CT, (18)F-FDG PET/CT, and complete per

22 All patients underwent contrast-enhanced CT, (18)F-FDG PET/CT, and complete per

23 head-to-head comparison versus (18)F-FDG or contrast-enhanced CT, (68)Ga-FAPI detected more tumor on

24 tial surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers.

25 east twice as high as the number detected by contrast-enhanced CT across the 6 studied peptide mass a

26 4% (123 of 8844) in the group that underwent contrast-enhanced CT and 1.6% (171 of 10 533) in the gro

27 iteria, 223 underwent intravenous and rectal contrast-enhanced CT and 193 underwent intravenous contr

28 as, whose cases constituted the basis for 10 contrast-enhanced CT and 5 MRI studies.

29 ergoing conventional imaging (abdominopelvic contrast-enhanced CT and bone scanning) and the other re

30 Subsequently, contrast-enhanced CT and contrast-enhanced MRI were perf

31 al US was performed, followed by multiphasic contrast-enhanced CT and liver MRI due to the findings o

32 Contrast-enhanced CT and MR venography were the most sen

33 ous bleomycin [day 8]), patients underwent a contrast-enhanced CT and PET scan (PET-2).

34 Patients underwent contrast-enhanced CT and PET/CT for staging and for resp

35 ET/CT depicts additional sites compared with contrast-enhanced CT and results in upstaging of disease

36 c, 155 underwent both preoperative ECG-gated contrast-enhanced CT and TEE.

37 rence between the performance of intravenous contrast-enhanced CT and that of rectal and intravenous

38 Preoperative staging with contrast-enhanced CT and/or MR scans was performed withi

39 hree institutions examined with preoperative contrast-enhanced CT and/or MRI between January 2008 and

40 e retrospectively acquired: a set of 102 non-contrast-enhanced CTs and a set of 96 contrast-enhanced

41 All patients underwent (68)Ga-FAPI46 PET/CT, contrast-enhanced CT, and (18)F-FDG PET/CT.

42 All of these patients underwent contrast-enhanced CT, and 38 patients additionally under

43 g digital subtraction angiography, SPECT/CT, contrast-enhanced CT, and anatomic illustrations.

44 (18)F-FDG PET/CT, contrast-enhanced CT, and nonenhanced CT were performed

45 phy before endovascular stent placement, (b) contrast-enhanced CT angiography 0-3 months after repair

46 by more than 2% on the nonenhanced CT image, contrast-enhanced CT angiography was performed immediate

47 etic valve dysfunction and underwent in vivo contrast-enhanced CT angiography, (18)F-fluoride PET, an

48 nd dipyridamole (82)Rb perfusion studies and contrast-enhanced CT angiography, using a 64-slice scann

49 early progression had measurable disease on contrast-enhanced CT at (18)F-FDG-avid sites at the end

50 A female hound cross underwent whole-body contrast-enhanced CT at a 2-mm slice thickness.

51 All patients underwent routine contrast-enhanced CT at the start and end of preoperativ

52 2 or greater esophageal tumors who underwent contrast-enhanced CT before and after CRT between 2005 a

53 e whether SPECT/CT and additional diagnostic contrast-enhanced CT before radioembolization with (90)Y

54 ablation of pulmonary veins after undergoing contrast-enhanced CT between 2017 and 2021.

55 LSVR, and spleen volumes were measured with contrast-enhanced CT by radiologists and the DL model.

56 Adrenal masses detected with contrast-enhanced CT can be characterized as benign or m

57 Whole-body imaging with contrast-enhanced CT can be used to identify occult thro

58 Intravenous low-osmolar contrast-enhanced CT can safely be used in patients with

59 This study aimed to compare contrast-enhanced CT (CE-CT) and (18)F-FDG PET/CT for re

60 hose of the current gold standards, that is, contrast-enhanced CT (ceCT) and (18)F-FDG PET/CT.

61 Although contrast-enhanced CT (ceCT) and 2-[(18)F]FDG PET/CT rema

62 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

63 y) with HL were prospectively evaluated with contrast-enhanced CT (CECT) and PET combined with low-do

64 was to assess the added diagnostic value of contrast-enhanced CT (CECT) as compared with unenhanced

65 Methods: All patients underwent contrast-enhanced CT (ceCT) for TNM staging before (68)G

66 to auto-contour liver segments and spleen on contrast-enhanced CT (CECT) images.

67 een studies were identified, with most using contrast-enhanced CT (CECT) imaging (n = 9) and the rema

68 k stratification model based on preoperative contrast-enhanced CT (CECT) nodal features to predict th

69 PET/CT and contrast-enhanced CT (CECT) of the abdomen were performe

70 bone lesion assessment by (18)F-FDG PET plus contrast-enhanced CT (ceCT) or BS plus ceCT, for patient

71 s and three regional hospitals who underwent contrast-enhanced CT (CECT) or noncontrast CT between Ja

72 ell carcinoma (HNSCC) fluorodeoxyglucose PET/contrast-enhanced CT (CECT) scans using Neck Imaging Rep

73 Contrast-enhanced CT (CECT) using CA4+ reveals significa

74 ensitive than contrast-enhanced MRI (ceMRI), contrast-enhanced CT (ceCT), GLP-1R SPECT/CT, somatostat

75 pecificity of (99m)Tc-sestamibi SPECT/CT and contrast-enhanced CT (ceCT).

76 bstantiates a frequent occurrence of DARs at contrast-enhanced CT compared with that in control subje

77 ; concurrent or subsequent imaging findings (contrast-enhanced CT, contrast-enhanced MRI, sonography,

78 exendin PET/CT than for DOTA-SSA PET/CT and contrast-enhanced CT/contrast-enhanced diffusion-weighte

79 OTA-SSA PET/CT (64.8%; 95% CI, 50.6%-77.3%), contrast-enhanced CT/contrast-enhanced diffusion-weighte

80 Use of contrast-enhanced CT coronary angiography for detection,

81 ease in size or a 15% decrease in density on contrast-enhanced CT, correlated well in a small trainin

82 Response at interim PET/CT and contrast-enhanced CT could not predict progression-free

83 sis for PET/CT (PET criteria) and multiphase contrast-enhanced CT (CT criteria) in separate sessions.

84 Archival dynamic contrast-enhanced CT data from 46 patients with colorect

85 ic contrast-enhanced MR imaging (DCEMRI) and contrast-enhanced CT (DCECT) for hepatocellular carcinom

86 Patients were followed up with contrast-enhanced CT every 2-4 months.

87 adult and pediatric patients who underwent a contrast-enhanced CT examination at the institution from

88 cion of a thrombus, which was confirmed on a contrast-enhanced CT examination.

89 re (10,121 unenhanced and 10,121 intravenous contrast-enhanced CT examinations in 20,242 patients).

90 erial propagation can be applied to simulate contrast-enhanced CT examinations.

91 A total of 1930 contrast-enhanced CT exams with reference standard manua

92 Anatomic images were obtained by contrast-enhanced CT, facilitating clear delineation of

93 Visual- and density-based analysis on contrast-enhanced CT failed to differentiate affected fr

94 Subsequently, contrast-enhanced CT (Fig 2) and contrast-enhanced MRI (

95 ilter value, 1.8; slope = -0.0008; P = .003; contrast-enhanced CT: filter value, 1.8; slope = -0.0006

96 36 and .002, respectively) and posttreatment contrast-enhanced CT findings could predict OS (P = .035

97 Posttreatment PET/CT and contrast-enhanced CT findings could predict PFS (P = .03

98 premedication regimen before low-osmolality contrast-enhanced CT for a prior allergic-like or unknow

99 CT was approximately 30% less accurate than contrast-enhanced CT for evaluating abdominal pain in th

100 adult ED patients who underwent dual-energy contrast-enhanced CT for the evaluation of acute abdomin

101 by (68)Ga-satoreotide trizoxetan relative to contrast-enhanced CT (for each of the 6 peptide mass and

102 nal) are trained with paired noncontrast and contrast enhanced CTs from seventy-five patients (total

103 he tumor stage at nonehanced CT increased at contrast-enhanced CT, from IA to IIA (n = 1), IIB to IV

104 ive patients with new-onset dyspnea [four in contrast-enhanced CT group and one in unenhanced CT grou

105 ptom exacerbations within 1 day of CT in the contrast-enhanced CT group compared with the unenhanced

106 The contrast-enhanced CT group was associated with a signifi

107 In the contrast-enhanced CT group, AKI incidence was higher in

108 nd one patient with progressive weakness [in contrast-enhanced CT group]).

109 tients with progressive dyspnea [both in the contrast-enhanced CT group], and one patient with progre

110 The unenhanced and contrast-enhanced CT groups had similar thymectomy rates

111 Intravenous and rectal contrast-enhanced CT had a sensitivity of 92% (95% confi

112 Intravenous contrast-enhanced CT had a sensitivity of 93% (95% CI: 8

113 Patients who underwent contrast-enhanced CT had an increased amount of DNA radi

114 ith corticosteroids beginning 5 hours before contrast-enhanced CT has a breakthrough reaction rate no

115 nderwent ultrasonography (US) and subsequent contrast-enhanced CT if US imaging yielded negative or i

116 Figure 4: Axial contrast-enhanced CT image of the abdomen.

117 rning algorithm to segment adrenal glands on contrast-enhanced CT images and classify glands as norma

118 Figure 2b: (a) Axial and (b) coronal contrast-enhanced CT images of the upper abdomen obtaine

119 Figure 2a: (a) Axial and (b) coronal contrast-enhanced CT images of the upper abdomen obtaine

120 ure 1b: (a) Axial and (b) curved reformatted contrast-enhanced CT images of the upper abdomen.

121 ure 1a: (a) Axial and (b) curved reformatted contrast-enhanced CT images of the upper abdomen.

122 quantified from medium to coarse texture on contrast-enhanced CT images showed significant associati

123 ium to coarse texture on both unenhanced and contrast-enhanced CT images showed significant inverse a

124 tomatic segmentation and the ground truth on contrast-enhanced CT images were 0.80 +/- 0.08, 0.89 +/-

125 y-Five patients with paired non-contrast and contrast-enhanced CT images were randomly selected from

126 ty-Five patients with paired noncontrast and contrast-enhanced CT images were randomly selected from

127 an index of PD severity) was evaluated using contrast-enhanced CT images while blinded to clinical an

128 evaluated detection of pancreatic cancer on contrast-enhanced CT images, detection of prostate cance

129 e detection of liver metastases on abdominal contrast-enhanced CT images.

130 Patients underwent FDG-PET/CT and contrast-enhanced CT imaging 8 weeks after completion of

131 Contrast-enhanced CT imaging revealed thoracic aortitis

132 Unenhanced (Fig 1) and multiphasic contrast-enhanced CT imaging was performed in arterial (

133 Unenhanced and multiphasic contrast-enhanced CT imaging was performed in arterial,

134 Conclusion Adding unenhanced CT to contrast-enhanced CT improved the sensitivity, diagnosti

135 essment models, minimum density analysis and contrast enhanced-CT in the relative subgroups of nodule

136 erall incidence of acute kidney injury after contrast-enhanced CT in children and adolescents was ver

137 hanced CT and that of rectal and intravenous contrast-enhanced CT in children suspected of having app

138 e of AKI, dialysis, or death attributable to contrast-enhanced CT in patients with a solitary kidney

139 ents were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel and/or liver or spleen

140 phy (CT) with that of intravenous and rectal contrast-enhanced CT in the evaluation of children suspe

141 ation of CLMs, to reduce or avoid the use of contrast-enhanced CT in the paediatric population.

142 non-inferiority to radiology reports (using contrast-enhanced CT) in the differentiation of common p

143 Of 7692 women, 1012 (13.2%) underwent contrast-enhanced CT including liver assessment.

144 er enhancing tumor burden (LETB) assessed at contrast-enhanced CT indicates early response and helps

145 ely quantify TD lymphatic flow using dynamic contrast-enhanced CT lymphangiography.

146 tic flow measurement technique using dynamic contrast-enhanced CT lymphangiography.

147 Either PET/CT or contrast-enhanced CT may be used for response assessment

148 luded in estimating the risk associated with contrast-enhanced CT, may still not fully characterize t

149 correlations were seen between conventional contrast-enhanced CT measurements of fECS and both the I

150 Contrast-enhanced CT measurements of fECS and MMCM uptak

151 Changes in dynamic contrast-enhanced CT measures of tumour relative blood v

152 Subtraction maps (contrast-enhanced CT minus precontrast CT) were calculat

153 99m)Tc-labeled human serum albumin SPECT and contrast-enhanced CT/MRI and defined the following dosim

154 All lesions at contrast-enhanced CT (n = 5) enhanced.

155 patient underwent surveillance imaging with contrast-enhanced CT of the abdomen and pelvis in the ve

156 patient underwent surveillance imaging with contrast-enhanced CT of the abdomen and pelvis in the ve

157 Initial evaluation with contrast-enhanced CT of the abdomen and pelvis was perfo

158 Initial evaluation with contrast-enhanced CT of the abdomen and pelvis was perfo

159 Initial evaluation with contrast-enhanced CT of the abdomen and pelvis was perfo

160 Contrast-enhanced CT of the chest, abdomen, and pelvis (

161 Contrast-enhanced CT of the chest, abdomen, and pelvis w

162 Contrast-enhanced CT of the chest, abdomen, and pelvis w

163 Contrast-enhanced CT of the chest, abdomen, and pelvis w

164 Contrast-enhanced CT of the chest, abdomen, and pelvis w

165 n approximately 1% of patients who underwent contrast-enhanced CT of the chest.

166 Noncontrast and contrast-enhanced CT of the head (Fig 1) and CT angiogra

167 Noncontrast and contrast-enhanced CT of the head and CT angiography were

168 ocedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis.

169 Use of both HAP and PVP contrast-enhanced CT optimizes the evaluation of patient

170 llance unless there is measurable disease on contrast-enhanced CT or clinical suspicion of active dis

171 erest (VOIs) were delineated on pretreatment contrast-enhanced CT or MR images according to Couinaud

172 SPECT with coregistered contrast-enhanced CT or MR imaging and SPECT/CT images o

173 dard imaging, including routine preoperative contrast-enhanced CT or MRI of the brain, PET of the bra

174 The primary advantages of CEUS compared with contrast-enhanced CT or MRI relate to its superior contr

175 sease sites and two fewer disease sites than contrast-enhanced CT (P = .0003).

176 th-hold T1-weighted MP-GRE imaging than with contrast-enhanced CT, particularly when breath-hold imag

177 disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and

178 prior intravenous contrast extravasation for contrast-enhanced CT performed earlier during the day an

179 was to examine whether (18)F-FDG PET/CT and contrast-enhanced CT performed immediately after percuta

180 that are helpful in evaluating SPNs such as contrast-enhanced CT, PET/CT imaging and also pathologic

181 the diameter of the bulging submucosal EV on contrast-enhanced CT, presence of portal vein thrombosis

182 However, contrast-enhanced CT pulmonary angiography (CTPA) has sh

183 Helical biphasic contrast-enhanced CT represents a considerable improveme

184 Long-term follow-up by way of a contrast-enhanced CT revealed no recanalization of the t

185 Contrast-enhanced CT revealed partial remission in 5, st

186 f preoperative imaging with USG, Doppler and contrast enhanced CT scan can provide correct diagnosis.

187 n of heavy analgesic users to render the non-contrast-enhanced CT scan a sensitive tool to detect ana

188 (CTS level 1); imaging, including at least 1 contrast-enhanced CT scan and 1 [(68)Ga]Ga-PSMA-11 PET/C

189 The abdominal contrast-enhanced CT scan evidenced acute lesions of the

190 ey phantoms was designed on the basis of the contrast-enhanced CT scan of a patient with metastatic c

191 thout moving the patient, we performed a non-contrast-enhanced CT scan of the same body region.

192 A contrast-enhanced CT scan showed a big mass of soft tiss

193 A late portal phase contrast-enhanced CT scan was used to contour the liver

194 e of gas and/or stool, in conjunction with a contrast-enhanced CT scan, for patients with previous ab

195 years) with a history of seizures underwent contrast-enhanced CT scan.

196 2 MBq) of (64)Cu-DOTATATE after a diagnostic contrast-enhanced CT scan.

197 l to estimate single-kidney GFR with dynamic contrast-enhanced CT scanning.

198 rolled to undergo both standard and low-dose contrast enhanced CT scans, which were categorized as no

199 linical test dataset of both noncontrast and contrast-enhanced CT scans acquired at a level I trauma

200 We obtained preoperative, contrast-enhanced CT scans and corresponding pathology r

201 alyzes whole-liver regions from preoperative contrast-enhanced CT scans for predicting recurrence-fre

202 We extracted L3 SMA using non-contrast-enhanced CT scans from healthy adults, split in

203 a mid-vertebral and inferior slice using non-contrast-enhanced CT scans from healthy, adult kidney do

204 Contrast-enhanced CT scans in 44 children with pneumonia

205 On (18)F-FDG PET/CT and coregistered contrast-enhanced CT scans of 159 females (age, 16-81 y)

206 ure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumo

207 Patients with both available contrast-enhanced CT scans taken before the bleeding epi

208 (18)F-FDG PET/CT and contrast-enhanced CT scans were acquired every 3 mo.

209 and coronal) T1-weighted MP-GRE images, and contrast-enhanced CT scans were analyzed.

210 ceeding to surgical resection with available contrast-enhanced CT scans were included.

211 On portal venous phase contrast-enhanced CT scans, attenuation greater than 70

212 On contrast-enhanced CT scans, macroscopic fat (<-30 HU) wa

213 On contrast-enhanced CT scans, the models had a mean AUC of

214 etween routine-dose (RD) and lower-dose (LD) contrast-enhanced CT scans, with and without Digital Ima

215 h follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans.

216 Contrast-enhanced CT serves as a useful imaging tool for

217 lignant PNST that arose in a ganglioneuroma, contrast-enhanced CT showed a large, markedly heterogene

218 Baseline PET/CT and contrast-enhanced CT showed concordance in depiction of

219 rospective assessments of 164 unenhanced and contrast-enhanced CT studies from 158 consecutive patien

220 erials and Methods Retrospectively collected contrast-enhanced CT studies in patients diagnosed with

221 AKI was prevalent in both the unenhanced and contrast-enhanced CT subgroups, and it increased with in

222 Continued growth in the use of contrast-enhanced CT suggests a need for greater awarene

223 lyceride-enhanced CT (126 mg I/kg), and dual-contrast-enhanced CT (triglyceride plus iohexol [425 mg

224 years) with 101 adrenal lesions depicted at contrast-enhanced CT underwent delayed (mean, 9 minutes)

225 Two days later, 6 pigs again underwent contrast-enhanced CT, using a low-radiation-dose approac

226 Results were compared with contrast-enhanced CT, using standardized criteria of mal

227 (82)Rb PET with simultaneous high-resolution contrast-enhanced CT ventriculography, obtained as a byp

228 A total of 20 contrast-enhanced CT volume scans were acquired in 5 swi

229 onset of symptom progression, 2.5 days with contrast-enhanced CT vs 14.0 days with unenhanced CT; P

230 lete response versus no complete response at contrast-enhanced CT was analyzed by using Kaplan-Meier

231 Conclusion Contrast-enhanced CT was associated with higher risk of

232 SPECT imaging quantification based on contrast-enhanced CT was reproducible (interexperimenter

233 < .05), and attenuation differences at dual-contrast-enhanced CT were comparable to those at CTAP.

234 sitivity values for lesion detection at dual-contrast-enhanced CT were greater than those at iohexol-

235 Physical examination and contrast-enhanced CT were performed 30 days after comple

236 tion from 2019 to 2020 who underwent TTE and contrast-enhanced CT were retrospectively studied women,

237 ARs that were significantly more frequent at contrast-enhanced CT were skin rash (P = .0311), skin re

238 oncologic patients studied with intravenous-contrast-enhanced CT, where the group of metastases had

239 reach a CLM diagnosis in good agreement with contrast-enhanced CT, which is considered the gold stand

240 ars) with decreased renal function underwent contrast-enhanced CT with either iso-osmolality iodixano

241 Each patient also underwent non-contrast-enhanced CT within 3 months of the contrast-enh

242 cohort (n = 1425) of patients who underwent contrast-enhanced CT without premedication and who had s